Long-term outcomes in KEYNOTE-052: Phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer - Vuky, J; Balar, A V; Castellano, D (J Clin Oncol, 2020)